Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Ana Alcaraz-SernaDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9452-6788
Noémie Chillier *Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0000-1812-1626
Aurélien Trompette *Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-5244-0823
Laura ErmellinoDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3378-1785
Raphaël PorretDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-2781-9250
Erica LanaDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3518-0107
Rebecca CecchinDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-8770-1940
Apiha ShanmuganathanDivision of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-5124-2906
Seher GuneyDivision of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0009-0004-6490-3724
Oscar Alfageme-AbelloDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9963-7137
Eleonora PaceDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0004-6898-1201
Antonio MancarellaDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1174-872X
Jeremy CamposDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0008-1202-7418
Mathilde FoglieriniDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7538-4262
Christophe von GarnierDivision of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3585-9176
Craig FenwickDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9435-0110
Laurent PerezDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-8860-7928
Niki UbagsDivision of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0177-4134
Yannick D MullerDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0513-7156
Funding
Gabriella Giorgi-Cavaglieri FoundationMachaon FoundationMartin Escudero Foundation
6 · The paper itself
Abstract
Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation. · full record | OpenQuestion